KR101882521B1 - 적혈구 수준을 증가시키기 위한 ｇｄｆ 트랩과 에리트로포이에틴 수용체 활성인자의 병용 - Google Patents

적혈구 수준을 증가시키기 위한 ｇｄｆ 트랩과 에리트로포이에틴 수용체 활성인자의 병용 Download PDF

Info

Publication number
KR101882521B1
KR101882521B1 KR1020127004678A KR20127004678A KR101882521B1 KR 101882521 B1 KR101882521 B1 KR 101882521B1 KR 1020127004678 A KR1020127004678 A KR 1020127004678A KR 20127004678 A KR20127004678 A KR 20127004678A KR 101882521 B1 KR101882521 B1 KR 101882521B1
Authority
KR
South Korea
Prior art keywords
glu
leu
gly
pro
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020127004678A
Other languages
English (en)
Korean (ko)
Other versions
KR20120054024A (ko
Inventor
자스비르 세라
로버츠 스코트 피어사르
라빈드라 쿠마르
Original Assignee
악셀레론 파마 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2009/004659 external-priority patent/WO2010019261A1/en
Application filed by 악셀레론 파마 인코포레이티드 filed Critical 악셀레론 파마 인코포레이티드
Publication of KR20120054024A publication Critical patent/KR20120054024A/ko
Application granted granted Critical
Publication of KR101882521B1 publication Critical patent/KR101882521B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/1103—Receptor protein serine/threonine kinase (2.7.11.30)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020127004678A 2009-08-13 2010-08-13 적혈구 수준을 증가시키기 위한 ｇｄｆ 트랩과 에리트로포이에틴 수용체 활성인자의 병용 Active KR101882521B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
PCT/US2009/004659 WO2010019261A1 (en) 2008-08-14 2009-08-13 Use of gdf traps to increase red blood cell levels
US12/583,177 2009-08-13
US12/583,177 US8058229B2 (en) 2008-08-14 2009-08-13 Method of increasing red blood cell levels or treating anemia in a patient
WOPCT/US2009/004659 2009-08-13
US30590110P 2010-02-18 2010-02-18
US61/305,901 2010-02-18
PCT/US2010/045509 WO2011020045A1 (en) 2009-08-13 2010-08-13 Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020187020803A Division KR20180085825A (ko) 2009-08-13 2010-08-13 적혈구 수준을 증가시키기 위한 ｇｄｆ 트랩과 에리트로포이에틴 수용체 활성인자의 병용

Publications (2)

Publication Number Publication Date
KR20120054024A KR20120054024A (ko) 2012-05-29
KR101882521B1 true KR101882521B1 (ko) 2018-07-27

Family

ID=43586530

Family Applications (5)

Application Number Title Priority Date Filing Date
KR1020127004678A Active KR101882521B1 (ko) 2009-08-13 2010-08-13 적혈구 수준을 증가시키기 위한 ｇｄｆ 트랩과 에리트로포이에틴 수용체 활성인자의 병용
KR1020187020803A Ceased KR20180085825A (ko) 2009-08-13 2010-08-13 적혈구 수준을 증가시키기 위한 ｇｄｆ 트랩과 에리트로포이에틴 수용체 활성인자의 병용
KR1020197027722A Active KR102170682B1 (ko) 2009-08-13 2010-08-13 적혈구 수준을 증가시키기 위한 ｇｄｆ 트랩과 에리트로포이에틴 수용체 활성인자의 병용
KR1020207030283A Ceased KR20200124322A (ko) 2009-08-13 2010-08-13 적혈구 수준을 증가시키기 위한 ｇｄｆ 트랩과 에리트로포이에틴 수용체 활성인자의 병용
KR1020227045338A Active KR102606494B1 (ko) 2009-08-13 2010-08-13 적혈구 수준을 증가시키기 위한 ｇｄｆ 트랩과 에리트로포이에틴 수용체 활성인자의 병용

Family Applications After (4)

Application Number Title Priority Date Filing Date
KR1020187020803A Ceased KR20180085825A (ko) 2009-08-13 2010-08-13 적혈구 수준을 증가시키기 위한 ｇｄｆ 트랩과 에리트로포이에틴 수용체 활성인자의 병용
KR1020197027722A Active KR102170682B1 (ko) 2009-08-13 2010-08-13 적혈구 수준을 증가시키기 위한 ｇｄｆ 트랩과 에리트로포이에틴 수용체 활성인자의 병용
KR1020207030283A Ceased KR20200124322A (ko) 2009-08-13 2010-08-13 적혈구 수준을 증가시키기 위한 ｇｄｆ 트랩과 에리트로포이에틴 수용체 활성인자의 병용
KR1020227045338A Active KR102606494B1 (ko) 2009-08-13 2010-08-13 적혈구 수준을 증가시키기 위한 ｇｄｆ 트랩과 에리트로포이에틴 수용체 활성인자의 병용

Country Status (13)

Country Link
EP (3) EP3117829B1 (enExample)
JP (4) JP5909446B2 (enExample)
KR (5) KR101882521B1 (enExample)
CN (7) CN113082194B (enExample)
AU (1) AU2010282361B2 (enExample)
BR (2) BR122020019169B1 (enExample)
CA (1) CA2770822C (enExample)
ES (2) ES2796121T3 (enExample)
IL (6) IL287990B (enExample)
MX (2) MX2012001916A (enExample)
NZ (3) NZ623113A (enExample)
RU (2) RU2642302C1 (enExample)
WO (1) WO2011020045A1 (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3059245B1 (en) 2004-07-23 2018-11-07 Acceleron Pharma Inc. Actrii receptor antagonistic antibodies
MX2008006626A (es) 2005-11-23 2008-09-24 Acceleron Pharma Inc Antagonistas de activin-actriia y usos para promover el crecimiento de huesos.
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
WO2008094708A2 (en) 2007-02-01 2008-08-07 Acceleron Pharma Inc. Activin-actriia antagonists and uses for treating or preventing breast cancer
TWI782836B (zh) 2007-02-02 2022-11-01 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
TWI606062B (zh) 2007-02-09 2017-11-21 艾瑟勒朗法瑪公司 包含ＡｃｔＲＩＩａ-Ｆｃ融合蛋白的醫藥組合物；ＡｃｔＲＩＩａ-Ｆｃ融合蛋白於治療或預防與癌症相關的骨質流失之用途；ＡｃｔＲＩＩａ-Ｆｃ融合蛋白於治療或預防多發性骨髓瘤之用途
WO2009038745A1 (en) 2007-09-18 2009-03-26 Acceleron Pharma Inc. Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
HRP20191109T1 (hr) 2008-08-14 2019-09-20 Acceleron Pharma Inc. Gdf klopke za uporabu u liječenju anemije
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
WO2010083034A1 (en) 2009-01-13 2010-07-22 Acceleron Pharma Inc. Methods for increasing adiponectin
AU2010258931B2 (en) 2009-06-08 2015-04-23 Acceleron Pharma Inc. Methods for increasing thermogenic adipocytes
CN107267520A (zh) 2009-06-12 2017-10-20 阿塞勒隆制药公司 截短的actriib‑fc融合蛋白
CA2781152A1 (en) 2009-11-17 2011-05-26 Acceleron Pharma Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
JP2014502260A (ja) 2010-11-08 2014-01-30 アクセルロン ファーマ， インコーポレイテッド Ａｃｔｒｉｉａ結合剤およびその使用
EA202090053A3 (ru) * 2011-10-17 2020-06-30 Акселерон Фарма, Инк. Способы и композиции для лечения неэффективного эритропоэза
US9809636B2 (en) 2012-04-06 2017-11-07 Acceleron Pharma Inc. Methods for increasing red blood cell levels comprising administering BMP9
IL290653B2 (en) * 2012-10-24 2025-05-01 Celgene Corp Biomarker for use in the treatment of anemia
AU2013334660B2 (en) * 2012-10-24 2018-08-09 Celgene Corporation Methods for treating anemia
ES2884095T3 (es) 2012-11-02 2021-12-10 Celgene Corp Antagonistas de activina-actrii y usos para el tratamiento de trastornos óseos y otros trastornos
JP2017509647A (ja) * 2014-03-21 2017-04-06 アクセルロン ファーマ， インコーポレイテッド アクチビンｂおよび／またはｇｄｆ１１の阻害によって赤血球レベルを増大させ、無効赤血球生成を処置する方法
MA40008A (fr) * 2014-06-13 2021-05-05 Acceleron Pharma Inc Antagoniste actrii pour le traitement et la prevention d'un ulcere cutane chez un sujet ayant l'anemie
MA41052A (fr) * 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
WO2016069925A1 (en) 2014-10-30 2016-05-06 Acceleron Pharma Inc. Methods and compositions using gdf15 polypeptides for increasing red blood cells
AU2015358469B2 (en) 2014-12-03 2021-05-27 Acceleron Pharma Inc. Activin-ActRII antagonists and uses for treating anemia
MA41119A (fr) * 2014-12-03 2017-10-10 Acceleron Pharma Inc Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
WO2016128523A1 (en) * 2015-02-12 2016-08-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the responsiveness of a patient affected with malignant hematological disease to chemotherapy treatment and methods of treatment of such disease
SG10201913747PA (en) 2015-04-22 2020-03-30 Biogen Ma Inc Novel hybrid actriib ligand trap proteins for treating muscle wasting diseases
JP2018522579A (ja) 2015-05-20 2018-08-16 セルジーン コーポレイション アクチビンＩＩ型受容体リガンドトラップを使用するβ−サラセミアのインビトロ細胞培養法
WO2017079591A2 (en) * 2015-11-04 2017-05-11 Acceleron Pharma Inc. Methods for increasing red blood cell levels and treating ineffective erythropoiesis
AU2016359695A1 (en) 2015-11-23 2018-06-14 Acceleron Pharma Inc. Methods for treating eye disorders
US20170240639A1 (en) * 2016-02-22 2017-08-24 Acceleron Pharma Inc. Actrii antagonists for use in increasing immune activity
HUE054228T2 (hu) 2016-07-15 2021-08-30 Acceleron Pharma Inc Használható actriia polipeptideket tartalmazó összetételek a pulmonalis hypertónia kezelésében történõ alkalmazásra
PL3490582T3 (pl) * 2016-07-27 2024-09-23 Acceleron Pharma Inc. Kompozycje do zastosowania w leczeniu mielofibrozy
CN110036025B (zh) 2016-10-05 2024-03-22 阿塞勒隆制药公司 变体ActRIIB蛋白及其用途
EP3522934A4 (en) 2016-10-05 2020-04-15 Acceleron Pharma Inc. COMPOSITIONS AND METHODS FOR TREATING KIDNEY DISEASES
JOP20190085A1 (ar) 2016-10-20 2019-04-17 Biogen Ma Inc طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة
WO2018089715A1 (en) 2016-11-10 2018-05-17 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
PT3638243T (pt) 2017-06-14 2024-10-31 Celgene Corp Métodos para tratamento da mielofibrose e anemia associadas ao neoplasma mieloproliferativo
JP7258021B2 (ja) 2017-11-09 2023-04-14 ケロス セラピューティクス インコーポレイテッド アクチビンＩＩａ型受容体変異体を含む医薬組成物
IL320014A (en) 2018-01-12 2025-06-01 Keros Therapeutics Inc Activin receptor type iib variants and methods of use thereof
CN112601538B (zh) * 2018-05-09 2025-08-19 科乐斯疗法公司 激活素受体iia型变体及其使用方法
US12310982B2 (en) 2018-12-10 2025-05-27 Elena Valentinovna ARSHINTSEVA Use of the poloxamer as a pharmacologically active substance
EP4121088A4 (en) 2020-03-20 2024-07-03 Keros Therapeutics, Inc. Methods of using activin receptor type iib variants
CN111466337B (zh) * 2020-05-19 2022-04-19 山东大学齐鲁医院 一种腹主动脉瘤动物模型及其构建方法
US12186370B1 (en) 2020-11-05 2025-01-07 Celgene Corporation ACTRIIB ligand trap compositions and uses thereof
CN115317589B (zh) * 2022-09-05 2024-12-13 中国海洋大学 脯氨酰羟化酶抑制剂及其应用
CN119198238A (zh) * 2024-09-18 2024-12-27 广东省安家医健健康管理有限公司 一种地中海贫血检测系统及试剂盒

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008076437A2 (en) 2006-12-18 2008-06-26 Acceleron Pharma Inc. Activin-actrii antagonists and uses for increasing red blood cell levels
WO2008097541A2 (en) 2007-02-02 2008-08-14 Acceleron Pharma Inc. Variants derived from actriib and uses therefor

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1265208A (en) 1915-09-07 1918-05-07 Edward C Kahn Liquid-fuel burner.
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
WO1990008822A1 (en) 1989-02-03 1990-08-09 Genetics Institute, Inc. Erythropoietin receptor
US5677196A (en) 1993-05-18 1997-10-14 University Of Utah Research Foundation Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays
US5525490A (en) 1994-03-29 1996-06-11 Onyx Pharmaceuticals, Inc. Reverse two-hybrid method
US5885574A (en) 1994-07-26 1999-03-23 Amgen Inc. Antibodies which activate an erythropoietin receptor
US5814565A (en) 1995-02-23 1998-09-29 University Of Utah Research Foundation Integrated optic waveguide immunosensor
DE69636866D1 (en) 1995-04-11 2007-03-15 Gen Hospital Corp Reverse "two-hybrid"-systeme
CA2359242C (en) 1999-01-21 2009-12-08 Metamorphix, Inc. Growth differentiation factor inhibitors and uses therefor
PT1311285E (pt) * 2000-05-15 2005-06-30 Hoffmann La Roche Composicao farmaceutica liquida contendo um derivado de eritropoietina
US7087224B2 (en) * 2000-10-31 2006-08-08 Amgen Inc. Method of treating anemia by administering IL-1ra
CN100522946C (zh) * 2001-12-06 2009-08-05 法布罗根股份有限公司 低氧诱导因子(HIF)α的稳定化
DE10234192B4 (de) * 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
WO2004069237A1 (en) * 2003-02-07 2004-08-19 Prometic Biosciences Inc. Medium-chain length fatty acids, glycerides and analogues as stimulators of erythropoiesis
GB0304424D0 (en) * 2003-02-26 2003-04-02 Glaxosmithkline Biolog Sa Novel compounds
EP3059245B1 (en) 2004-07-23 2018-11-07 Acceleron Pharma Inc. Actrii receptor antagonistic antibodies
EP1819357A4 (en) * 2004-12-09 2009-02-25 Univ Pittsburgh VACCINES FOR FAST RESPONSE TO A BIRD GRIP PANDEMY
WO2006115274A1 (ja) * 2005-04-26 2006-11-02 Ajinomoto Co., Inc. 骨髄赤血球前駆細胞分化促進剤
AU2006301582B2 (en) * 2005-10-07 2011-10-13 Msd Italia S.R.L. Matrix metalloproteinase 11 vaccine
US8067562B2 (en) 2005-11-01 2011-11-29 Amgen Inc. Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
WO2008073292A2 (en) * 2006-12-08 2008-06-19 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Method for protecting renal tubular epithelial cells from radiocontrast nephro parhy (rcn)
KR20190049912A (ko) * 2008-06-26 2019-05-09 악셀레론 파마 인코포레이티드 액티빈-ａｃｔｒｉｉａ의 길항물질 및 적혈구 수준을 증가시키기 위한 이들의 용도
HRP20191109T1 (hr) * 2008-08-14 2019-09-20 Acceleron Pharma Inc. Gdf klopke za uporabu u liječenju anemije

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008076437A2 (en) 2006-12-18 2008-06-26 Acceleron Pharma Inc. Activin-actrii antagonists and uses for increasing red blood cell levels
WO2008097541A2 (en) 2007-02-02 2008-08-14 Acceleron Pharma Inc. Variants derived from actriib and uses therefor

Also Published As

Publication number Publication date
CA2770822A1 (en) 2011-02-17
MX2012001916A (es) 2012-05-22
CN105535938A (zh) 2016-05-04
JP2018177816A (ja) 2018-11-15
RU2642302C1 (ru) 2018-01-24
CN102655872B (zh) 2016-01-20
CA2770822C (en) 2020-03-24
KR20120054024A (ko) 2012-05-29
RU2012109393A (ru) 2013-09-20
CN105561295A (zh) 2016-05-11
IL252044B (en) 2019-11-28
BR112012003232B1 (pt) 2022-02-22
RU2017145301A (ru) 2019-06-24
RU2020127574A (ru) 2022-02-21
CN105412908B (zh) 2021-08-24
HK1224199A1 (zh) 2017-08-18
ES2844123T3 (es) 2021-07-21
CN113577291A (zh) 2021-11-02
IL287990A (en) 2022-01-01
IL275851B (en) 2021-12-01
JP2016034981A (ja) 2016-03-17
EP3117829B1 (en) 2020-10-07
RU2017145301A3 (enExample) 2019-06-24
CN113171442A (zh) 2021-07-27
CN113171442B (zh) 2024-11-15
ES2796121T3 (es) 2020-11-25
AU2010282361A1 (en) 2012-03-15
IL252045A0 (en) 2017-06-29
KR102170682B1 (ko) 2020-10-28
BR112012003232A2 (pt) 2016-11-22
IL252046B (en) 2020-07-30
RU2732229C2 (ru) 2020-09-14
WO2011020045A1 (en) 2011-02-17
NZ712943A (en) 2017-08-25
EP2464369A1 (en) 2012-06-20
JP2020203953A (ja) 2020-12-24
RU2592670C2 (ru) 2016-07-27
BR122020019169B1 (pt) 2022-09-27
EP3838919A1 (en) 2021-06-23
JP2013501816A (ja) 2013-01-17
IL287990B (en) 2022-07-01
JP5909446B2 (ja) 2016-04-26
NZ623113A (en) 2015-10-30
KR102606494B1 (ko) 2023-11-24
AU2010282361B2 (en) 2015-03-19
EP3117829A1 (en) 2017-01-18
IL252045B (en) 2020-05-31
CN105412908A (zh) 2016-03-23
KR20200124322A (ko) 2020-11-02
IL252046A0 (en) 2017-06-29
IL252044A0 (en) 2017-06-29
KR20230003452A (ko) 2023-01-05
CN105561295B (zh) 2020-03-20
CN102655872A (zh) 2012-09-05
CN105535938B (zh) 2022-04-26
NZ598348A (en) 2014-05-30
CN113082194B (zh) 2025-03-18
KR20180085825A (ko) 2018-07-27
EP2464369A4 (en) 2013-07-17
CN113082194A (zh) 2021-07-09
WO2011020045A9 (en) 2011-06-03
IL218052A (en) 2017-05-29
KR20190111158A (ko) 2019-10-01
HK1223818A1 (zh) 2017-08-11
JP6860533B2 (ja) 2021-04-14
IL218052A0 (en) 2012-04-30
EP2464369B1 (en) 2020-03-11
MX2019010341A (es) 2019-10-21
IL275851A (en) 2020-08-31

Similar Documents

Publication Publication Date Title
KR101882521B1 (ko) 적혈구 수준을 증가시키기 위한 ｇｄｆ 트랩과 에리트로포이에틴 수용체 활성인자의 병용
US11155791B2 (en) Methods for treating anemia in a subject in need thereof
US20200181217A1 (en) Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels
AU2021290230A1 (en) Methods for treating fatty liver disease
EA034563B1 (ru) Способ лечения или предотвращения перегрузки железом у пациента с талассемией
RU2814047C2 (ru) Комбинированное применение ловушек gdf и активаторов рецепторов эритропоэтина для повышения содержания эритроцитов
AU2019222789B2 (en) Use of GDF traps to increase red blood cell levels
AU2019204127B2 (en) Combined use of GDF traps and erythropoietin receptor activators to increase red blood cell levels
HK1223818B (zh) Gdf捕获物和促红细胞生成素受体激活剂联合应用以增加红细胞水平
HK1224576B (zh) Gdf捕获物和促红细胞生成素受体激活剂联合应用以增加红细胞水平

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20120223

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20150812

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20170118

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20170926

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20170118

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20170926

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20170518

Comment text: Amendment to Specification, etc.

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20180123

Patent event code: PE09021S02D

AMND Amendment
PX0701 Decision of registration after re-examination

Patent event date: 20180423

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20180212

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20171226

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20170926

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20170518

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20180719

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20180720

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20180720

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20210707

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20220622

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20230626

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20240624

Start annual number: 7

End annual number: 7